Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by North Shore Long Island Jewish Health System
Sponsor:
Collaborators:
Feinstein Institute for Medical Research
Hofstra North Shore-LIJ School of Medicine
Information provided by (Responsible Party):
John A. Boockvar, Feinstein Institute for Medical Research
ClinicalTrials.gov Identifier:
NCT01269853
First received: December 22, 2010
Last updated: October 3, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2016
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)